Fruquintinib
- Generic Name
- Fruquintinib
- Brand Names
- Fruzaqla
- Drug Type
- Small Molecule
- Chemical Formula
- C21H19N3O5
- CAS Number
- 1194506-26-7
- Unique Ingredient Identifier
- 49DXG3M5ZW
- Background
Fruquintinib is under investigation for the treatment of NSCLC. Fruquintinib has been investigated for the treatment of ColoRectal Cancer.
- Indication
本品单药适用于既往接受过氟尿嘧啶类、奥沙利铂和伊立替康为基础的化疗，以及既往接受过或不适合接受抗血管内皮生长因子（VEGF）治疗、抗表皮生长因子受体（EGFR）治疗（RAS野生型）的转移性结直肠癌（mCRC）患者。
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Recruiting
- Conditions
- Refractory Colorectal CarcinomaMetastatic Colorectal CancerColorectal Cancer
- Interventions
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 20
- Registration Number
- NCT06221423
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
Phase 2
Not yet recruiting
- Conditions
- Colo-rectal Cancer
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Fujian Cancer Hospital
- Target Recruit Count
- 17
- Registration Number
- NCT06218888
Fruquintinib in Refractory Metastatic Colorectal Cancer: A Real-world Study
Completed
- Conditions
- Colorectal CancerRefractory Colorectal CancerMetastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 520
- Registration Number
- NCT06202417
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance
- First Posted Date
- 2024-01-11
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 124
- Registration Number
- NCT06202599
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)
- Conditions
- Colorectal Cancer
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2025-03-25
- Lead Sponsor
- Takeda
- Registration Number
- NCT06195514
Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC
Phase 2
Recruiting
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 40
- Registration Number
- NCT06168786
- Locations
- 🇨🇳
Huazhong University of Science and Technology, Wuhan, Hubei, China
Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Unresectable/Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2023-11-28
- Last Posted Date
- 2024-05-13
- Target Recruit Count
- 30
- Registration Number
- NCT06148402
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
- First Posted Date
- 2023-11-07
- Last Posted Date
- 2023-11-07
- Target Recruit Count
- 30
- Registration Number
- NCT06118762
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
Clinical Study of Fruquintinib Combined With Sintilimab and XELOX Regimen in the Treatment of Advanced Cancer
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Second Affiliated Hospital of Nanchang University
- Target Recruit Count
- 45
- Registration Number
- NCT06094868
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Completed
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2023-09-11
- Lead Sponsor
- Hunan Cancer Hospital
- Target Recruit Count
- 106
- Registration Number
- NCT06031376
- Locations
- 🇨🇳
Hunan Cancer hospital, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath